leisure time -WSS

leisure time

author：comprehensive 2025-08-18 11:30:41 - browse：34

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Petition to FDA: Get the lead out of consumer hair dyes

hotspot

explore

WSS

Cognito secures funding to test medical device for Alzheimer's

Medicare drug price negotiation’s day in court

Biden launches a new push to limit health care costs

Juul spent big to court Black leaders to promote its e

Charles Manson follower Leslie Van Houten released from prison after 53 years

Charles Manson follower Leslie Van Houten released from prison after 53 years

hotspot

leisure time

focus

In Memoriam: Notable people who died in 2023

HCA discloses massive data breach affecting 11 million patients

At least 13 dead in Texas as scorching temps continue

New research casts further doubt on a common procedure used with IVF

ChatGPT in medicine: STAT answers readers' burning questions

Woodcock on FDA’s accelerated approval and her next chapter

23andMe had bad news about my health. I wish a person had delivered it

Biden administration opens offers in Medicare drug price negotiations

How one medical school became remarkably diverse

FDA drug safety: Singulair case shows systemic surveillance flaws

leisure time

Biden launches a new push to limit health care costs

Lecanemab for Alzheimer's is coming. Is the health system ready?

Petition to FDA: Get the lead out of consumer hair dyes

Charles Manson follower Leslie Van Houten released from prison after 53 years

New research casts further doubt on a common procedure used with IVF

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

hotspot

hotspot

explore

focus